 Connection
Thomas Meyer to Cell Line, Tumor
This is a "connection" page, showing publications Thomas Meyer has written about Cell Line, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.074 |
|
|
|
-
Liu H, Yu L, Majerciak V, Meyer TJ, Yi M, Johnson PF, Cam M, Lowy DR, Zheng ZM. The long noncoding RNA lnc-FANCI-2 intrinsically restricts RAS signaling in human papillomavirus type 16-infected cervical cancer cells. Elife. 2025 Aug 29; 13.
Score: 0.035
-
Furusawa T, Cavero R, Liu Y, Li H, Xu X, Andresson T, Reinhold W, White O, Boufraqech M, Meyer TJ, Hartmann O, Diefenbacher ME, Pommier Y, Weyemi U. Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer. Mol Carcinog. 2024 Jun; 63(6):1024-1037.
Score: 0.031
-
Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004 Jul 15; 64(14):4931-41.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|